Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis. (21st October 2019)

• Record Type: Journal Article
• Authors: Zhu, Xiaolei; Wu, Shenhong
• Is Part Of: Cancer investigation. Volume 37:Number 9(2019)
• Page Start: 478
• Page End: 488
• Publication Date: 2019-10-21
• Subjects: Enzalutamide -- prostate cancer -- hypertension -- adverse event -- risk; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2019.1670203
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: Hypertension is associated with enzalutamide in the treatment of prostate cancer. We performed a meta-analysis of randomized clinical trials to determine the risk of hypertension. Databases including Pubmed and Google scholar were searched to identify randomized clinical trials with enzalutamide. A total of seven studies including 7347 patients were selected. The overall incidences of all-grade and high-grade hypertension were 11.9% (95%% CI: 8.8–16.0%) and 4.9% (95%% CI: 3.5–6.8%) respectively, with a relative risk of 2.82 (95%% CI: 2.34–3.38, p < 0.001) for all-grade and 2.27 (95%% CI: 1.73–2.96, p < 0.001) for high-grade. There was a significant risk of developing hypertension with enzalutamide.